JO
OBIO icon

John Overdeck’s Orchestra BioMed OBIO Stock Holding History

John Overdeck’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.4K Sell
22,563
-37,544
-62% -$154K ﹤0.01% 4890
2026
Q1 		$255K Sell
60,107
-26,445
-31% -$113K ﹤0.01% 4165
2025
Q4 		$359K Buy
+86,552
New +$349K ﹤0.01% 3498

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

John Overdeck's OBIO Position: Q2 2026 in Review

John Overdeck reduced its Orchestra BioMed (OBIO) stake by 62% in Q2 2026, selling an estimated $154K and leaving 22,563 shares worth $97.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4890.

John Overdeck first reported a position in OBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $359K in Q4 2025. 76 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • John Overdeck held 22,563 shares of Orchestra BioMed worth $97.4K as of Q2 2026.
  • John Overdeck sold 37,544 Orchestra BioMed shares in Q2 2026, an estimated $154K.
  • Orchestra BioMed made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4890 holding.
  • John Overdeck first reported a position in Orchestra BioMed in Q4 2025 and has held it in 3 quarters since.
  • John Overdeck's Orchestra BioMed position peaked at $359K in Q4 2025.
  • 76 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.